Patent RU-2735706-C1 (RU)
Inventor: PETRIK GALINA GEORGIEVNA
IPC: A61B5/00
Filed: 2019-07-24
Granted: 2020-11-06
Abstract: FIELD: medicine; endocrinology; cardiology; therapy; pathophysiology; preventive medicine. 
     SUBSTANCE: invention can be used for detecting and timely elimination of vascular lesions predictors at early stages of carbohydrate metabolism disorders. Method for prediction of risk of developing vascular lesions at early stages of carbohydrate metabolism disorders, including venous blood sampling, cholesterol level determination, characterized by that, additionally, the complex is used to determine deviation of anthropometric indicators (A), including body weight index (BWI), kg/m 2 , (A 1 ); waist circumference, cm, (A 2 ), prognostically safe values A 1 *<25 kg/m 2  and A 2 *<80 cm in females, <94 cm in males, respectively, biochemical indicators (B)—plasma glucose on an empty stomach, mmol/l, (B 1 ); glycated hemoglobin (HbA1c), %, (B 2 ); an index of insulin resistance (HOMA-IR), U (B 3 ); total cholesterol (TC), mmol/l (B 4 ); low-density lipoprotein cholesterol (LDL-C), mmol/l, (B 5 ); triglycerides (TG), mmol/l. (B 6 ); high-density lipoprotein cholesterol (HDL-C), mmol/l. (B 7 ); low-density lipoprotein cholesterol (CS-non-HDL), mmol/l. (B 8 ); alpha 2 -globulins, g/l. (B 9 ); beta 1 - globulins, g/l, (B 10 ); C-reactive protein (CRP), mg/, (B 11 ), uric acid, mcmol/l, (B 12 ); creatinine (B 13 ) micromole/l, alanine amino-transferase (ALT), µkat/l, (C 14 ), aspartate aminotransferase (ACT), µkat/l, (B 15 ) account prognostically safe value—B 1 *<6.1 mmol/l, B 2 *<6.0 mmol/l, B 3 *<2.5, B 4 *<4.5 mmol/l, B 5 *<2.5 mmol/l, B 6 *<1.7 mmol/l, B 7 *>1.0 mmol/l in males, >1.3 mmol/l in females, B 8 *<3.4 mmol/l, B 9 *<9.0 g/l, B 10 *<10.6 g/l, B 11 *<5 mg/l, B 12 *<339 mcmole/l, B 13 *<40 mkat/l, B 14 *<40 mkat/l, haemostasis—average thrombocyte volume, fl (H 1 ), intensity of ADP- and collagen-induced thrombocyte aggregation, % (H 2  and H 3 ), aPTT, c (H 4 ), fibrinogen, g/l, (H 5 ), VII factor activity, %. (H 6 ), antithrombin III, %, (H 7 ), plasminogen %, (H 8 ), endothelin pmol/l, (H 9), allow for prognostic safe values—H 1 *<10 fl, H 2 *<64 %, H 3 *<60 %, H 4 *>23 c, H 5 *<4 g/l, H 6 *<110 %, H 7 *>70 %, H 8 *>80 %, H 9 *<0.16 pmole/l respectively, then the difference between patient's values and prognostically safe values is determined (A 1 −A 1 *), (A 2 −A 2 *); (B 1 −B 1 *), (B 2 −B 2 *), (B 3 −B 3 *), (B 4 −B 4 *), (B 5 −B 5 *), (B 6 −B 6 *), (B 7 −B 7 *), (B 8 −B 8 *), (B 9 −B 9 *), (B 10 −B 10 *), (B 11 −B 11 *), (B 12 −B 12 *), (B 13 −B 13 *), (B 14 −B 14 *); (H 1 −H 1 *), (H 2 −H 2 *), (H 3 −H 3 *), (H 4 −H 4 *), (H 5 −H 5 *), (H 6 −H 6 *), (H 7 −H 7 *), (H 8 −H 8 *), (H 9 −H 9 *) respectively, and if a positive value of each of An−An*, Bn−Bn*, Hn−Hn* is 1 point, with zero or negative value of 0 points, total score (K) is determined as the sum of all the points, and if the positive sum is stated, the risk of developing vascular lesions is determined, and if the total score is zero, the risk is determined. 
     EFFECT: invention provides early detection and timely correction of anthropometric, biochemical and hemostasis disorders. 
     1 cl, 13 tbl, 2 ex